Safety and Efficacy Of Obinutuzumab (GA101) With Fludarabine/Cyclophosphamide (G-FC) Or Bendamustine (G-B) In The Initial Therapy Of Patients With Chronic Lymphocytic Leukemia (CLL)
Brown J, O'Brien S, Kingsley CD, et al.
Key Points:
Obinutuzumab, a novel glycoengineered, type II CD20 monoclonal antibody, has been approved by the FDA for use in combination with chlorambucil for patients with previously untreated CLL
Preliminary safety and efficacy of Obinutuzumab plus FC or B as upfront therapy in CLL demonstrated tolerable toxicity profile
Most common adverse events included infusion reactions which were not dose-limiting
Favorable clinical activity also noted
Implications:
- Combination may potentially improve outcomes in previously untreated patients
View the original abstract on the ASH website.
